Rinatabart Sesutecan

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NameRinatabart Sesutecan
Drug Alias NameRina-SPRO-1184GEN1184GEN-1184
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-FOLR1DNA topoisomerase I inhibitors
TargetsFolate receptor alphaDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsUterine Neoplasms +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[23] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesProfoundBio (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesProfoundBio (Suzhou) Co LtdJinmai Anbo Biopharmaceuticals (Suzhou) Co LtfGenmab A/S
Inactive CompaniesN/A
Active IndicationsSolid tumoursEndometrial NeoplasmsUterine Neoplasms +[12] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A